![\"\"](\"https:\/\/jamesfetzer.org\/wp-content\/uploads\/Johns-Hopkins-study-22disappears22-.jpg\")
<\/p>\nResearch Letter<\/a><\/h2>\n[Editor\u2019s note<\/strong>: We now have at least three sources of scientific studies that report there is no difference in the mortality rate with and without COVID-19, which means that its presence or absence appears to be statistically irrelevant (makes no difference), which in turn strongly suggests that its presence or absence is not causally relevant (that it is not causing people to die). These findings are consistent with and confirm my previous research on\u00a0The Coronavirus Phenomenon: Medical Emergency or Political Pandemic?<\/a>\u00a0In which case, we have (what may well be) the greatest hoax ever played upon the world since\u00a0the Moon Landing Hoax: How we Know we Didn\u2019t Go<\/a>, which, however, was not politically significant for the economic, physical and psychological future of the species.]\u00a0<\/em><\/p>\n<\/div>\nOctober 12, 2020<\/div>\nAlyssa\u00a0Bilinski,\u00a0MSc1<\/sup><\/a><\/span>;\u00a0<\/span>Ezekiel J.\u00a0Emanuel,\u00a0MD, PhD2<\/sup><\/a><\/span><\/div>\nAuthor Affiliations<\/a>\u00a0Article Information<\/a><\/div>\nJAMA.\u00a0<\/span>2020;324(20):2100-2102. doi:10.1001\/jama.2020.20717<\/span><\/div>\n<\/div>\n\n\nCOVID-19 Resource Center<\/a><\/div>\n<\/div>\n<\/div>\nThe patterns found for COVID-19\u2013specific deaths were similar for excess all-cause mortality<\/em><\/strong><\/div>\n\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<\/i>The US has experienced more deaths from coronavirus disease 2019 (COVID-19) than any other country and has one of the highest cumulative per capita death rates.1<\/a><\/sup>,2<\/a><\/sup>\u00a0An unanswered question is to what extent high US mortality was driven by the early surge of cases prior to improvements in prevention and patient management vs a poor longer-term response.3<\/a><\/sup>\u00a0We compared US COVID-19 deaths and excess all-cause mortality in 2020 (vs 2015-2019) to that of 18 countries with diverse COVID-19 responses.<\/p>\n\n\nMethods<\/h3>\n<\/div>\n
We compared the US with Organisation for Economic Co-operation and Development countries with populations exceeding 5 million and greater than $25\u202f000 per capita gross domestic product. For each country, we calculated the COVID-19 per capita mortality rate and grouped countries by mortality: (1) low (COVID-19 deaths, <5\/100\u202f000), (2) moderate (5-25\/100\u202f000), and (3) high (>25\/100\u202f000).1<\/a><\/sup>\u00a0We used Poisson regression for comparisons across countries.<\/p>\nWe calculated the difference in COVID-19 deaths between each country and the US through September 19, 2020 (week 38) under 3 scenarios: if the US had a comparable per capita COVID-19 mortality rate to each country from the start of the pandemic (February 13) or if the US mortality rate became comparable to other countries beginning May 10 or June 7, to allow lag time for policy interventions.3<\/a><\/sup>\u00a0(See the\u00a0Supplement<\/a>\u00a0for formulas.)<\/p>\n![\"\"](\"https:\/\/jamesfetzer.org\/wp-content\/uploads\/Johns-Hopkins-study-better-defined--300x236.jpg\")
The Johns Hopkins study showing no difference even in the elderly\u00a0mysteriously disappeared<\/a>.<\/em><\/figcaption><\/figure>\n\nResults<\/h3>\n<\/div>\n
On September 19, 2020, the US reported a total of 198\u202f589 COVID-19 deaths (60.3\/100\u202f000), higher than countries with low and moderate COVID-19 mortality but comparable with high-mortality countries (Table 1<\/a>). For instance, Australia (low mortality) had 3.3 deaths per 100\u202f000 and Canada (moderate mortality) had 24.6 per 100\u202f000. Conversely, Italy had 59.1 COVID-19 deaths per 100\u202f000; Belgium had 86.8 per 100\u202f000. If the US death rates were comparable to Australia, the US would have had 187\u202f661 fewer COVID-19 deaths (94% of reported deaths), and if comparable with Canada, 117\u202f622 fewer deaths (59%).<\/p>\nWhile the US had a lower COVID-19 mortality rate than high-mortality countries during the early spring, after May 10, all 6 high-mortality countries had fewer deaths per 100\u202f000 than the US. For instance, between May 10 and September 19, 2020, Italy\u2019s death rate was 9.1\/100\u202f000 while the US\u2019s rate was 36.9\/100\u202f000. If the US had comparable death rates with most high-mortality countries beginning May 10, it would have had 44\u202f210 to 104\u202f177 fewer deaths (22%-52%) (Table 1<\/a>). If the US had comparable death rates beginning June 7, it would have had 28% to 43% fewer reported deaths (as a percentage overall).<\/p>\nIn the 14 countries with all-cause mortality data, the patterns found for COVID-19\u2013specific deaths were similar for excess all-cause mortality (Table 2<\/a>). In countries with moderate COVID-19 mortality, excess all-cause mortality remained negligible throughout the pandemic. In countries with high COVID-19 mortality, excess all-cause mortality reached as high as 102.1\/100\u202f000 in Spain, while in the US it was 71.6\/100\u202f000. However, since May 10 and June 7, excess all-cause mortality was higher in the US than in all high-mortality countries (Table 2<\/a>).<\/p>\n![\"\"](\"https:\/\/jamesfetzer.org\/wp-content\/uploads\/COVID-deaths-non-reported-other-causes-300x244.jpg\")
Reported increase in CV deaths\u00a0almost equals exactly the decrease from all other causes.<\/a><\/em><\/figcaption><\/figure>\nDiscussion<\/h3>\n
Compared with other countries, the US experienced high COVID-19\u2013associated mortality and excess all-cause mortality into September 2020. After the first peak in early spring, US death rates from COVID-19 and from all causes remained higher than even countries with high COVID-19 mortality. This may have been a result of several factors, including weak public health infrastructure and a decentralized, inconsistent US response to the pandemic.4<\/a><\/sup>,5<\/a><\/sup><\/p>\nLimitations of this analysis include differences in mortality risk: the US population is younger but has more comorbidities compared with the other countries.6<\/a><\/sup>\u00a0In addition, since late August death rates have increased in several countries, and how mortality will compare with the US throughout fall remains unknown.<\/p>\n\nArticle Information<\/h3>\n<\/div>\n
<\/i>The US has experienced more deaths from coronavirus disease 2019 (COVID-19) than any other country and has one of the highest cumulative per capita death rates.1<\/a><\/sup>,2<\/a><\/sup>\u00a0An unanswered question is to what extent high US mortality was driven by the early surge of cases prior to improvements in prevention and patient management vs a poor longer-term response.3<\/a><\/sup>\u00a0We compared US COVID-19 deaths and excess all-cause mortality in 2020 (vs 2015-2019) to that of 18 countries with diverse COVID-19 responses.<\/p>\n We compared the US with Organisation for Economic Co-operation and Development countries with populations exceeding 5 million and greater than $25\u202f000 per capita gross domestic product. For each country, we calculated the COVID-19 per capita mortality rate and grouped countries by mortality: (1) low (COVID-19 deaths, <5\/100\u202f000), (2) moderate (5-25\/100\u202f000), and (3) high (>25\/100\u202f000).1<\/a><\/sup>\u00a0We used Poisson regression for comparisons across countries.<\/p>\n We calculated the difference in COVID-19 deaths between each country and the US through September 19, 2020 (week 38) under 3 scenarios: if the US had a comparable per capita COVID-19 mortality rate to each country from the start of the pandemic (February 13) or if the US mortality rate became comparable to other countries beginning May 10 or June 7, to allow lag time for policy interventions.3<\/a><\/sup>\u00a0(See the\u00a0Supplement<\/a>\u00a0for formulas.)<\/p>\n On September 19, 2020, the US reported a total of 198\u202f589 COVID-19 deaths (60.3\/100\u202f000), higher than countries with low and moderate COVID-19 mortality but comparable with high-mortality countries (Table 1<\/a>). For instance, Australia (low mortality) had 3.3 deaths per 100\u202f000 and Canada (moderate mortality) had 24.6 per 100\u202f000. Conversely, Italy had 59.1 COVID-19 deaths per 100\u202f000; Belgium had 86.8 per 100\u202f000. If the US death rates were comparable to Australia, the US would have had 187\u202f661 fewer COVID-19 deaths (94% of reported deaths), and if comparable with Canada, 117\u202f622 fewer deaths (59%).<\/p>\n While the US had a lower COVID-19 mortality rate than high-mortality countries during the early spring, after May 10, all 6 high-mortality countries had fewer deaths per 100\u202f000 than the US. For instance, between May 10 and September 19, 2020, Italy\u2019s death rate was 9.1\/100\u202f000 while the US\u2019s rate was 36.9\/100\u202f000. If the US had comparable death rates with most high-mortality countries beginning May 10, it would have had 44\u202f210 to 104\u202f177 fewer deaths (22%-52%) (Table 1<\/a>). If the US had comparable death rates beginning June 7, it would have had 28% to 43% fewer reported deaths (as a percentage overall).<\/p>\n In the 14 countries with all-cause mortality data, the patterns found for COVID-19\u2013specific deaths were similar for excess all-cause mortality (Table 2<\/a>). In countries with moderate COVID-19 mortality, excess all-cause mortality remained negligible throughout the pandemic. In countries with high COVID-19 mortality, excess all-cause mortality reached as high as 102.1\/100\u202f000 in Spain, while in the US it was 71.6\/100\u202f000. However, since May 10 and June 7, excess all-cause mortality was higher in the US than in all high-mortality countries (Table 2<\/a>).<\/p>\n Compared with other countries, the US experienced high COVID-19\u2013associated mortality and excess all-cause mortality into September 2020. After the first peak in early spring, US death rates from COVID-19 and from all causes remained higher than even countries with high COVID-19 mortality. This may have been a result of several factors, including weak public health infrastructure and a decentralized, inconsistent US response to the pandemic.4<\/a><\/sup>,5<\/a><\/sup><\/p>\n Limitations of this analysis include differences in mortality risk: the US population is younger but has more comorbidities compared with the other countries.6<\/a><\/sup>\u00a0In addition, since late August death rates have increased in several countries, and how mortality will compare with the US throughout fall remains unknown.<\/p>\nMethods<\/h3>\n<\/div>\n
Results<\/h3>\n<\/div>\n
Discussion<\/h3>\n
Article Information<\/h3>\n<\/div>\n